A Wnt1 regulated Frizzled-1/β-catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  L'Episcopo, Francesca ^a   Serapide, Maria F ^b   Tirolo, Cataldo ^a   Testa, Nunzio ^a   Caniglia, Salvatore ^a   Morale, Maria C ^a   Pluchino, Stefano ^c   Marchetti, Bianca ^a,d  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; DOPAMINE TRANSPORTER; FRIZZLED PROTEIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; WNT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL COUNT; CELL SURVIVAL; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

MOUSE MAMMARY TUMOR VIRUS; MUS;

EID: 79960123794     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-49     Document Type: Article

References (93)

1. Idiopathic and 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. Di Monte DA, Langston JW, Neuroglia Oxford University Press, Kettenmann H, Ransom BR, 1995 Chapter 65 997 989
2. Neurodegeneration and prospects for neuroprotection and rescue in Parkinson's disease. Olanow CW, Shapira AHV, Agid Y, Annal Neurology 2003 53 uppl 3
3. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT, Neurobiol Dis 2006 22 404 420 10.1016/j.nbd.2005.12.003 16439141 (Pubitemid 44294281)
4. Hormones are key actors in gene × environment interactions programming the vulnerability to Parkinson's disease: Glia as a common final pathway. Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC, Ann NY Acad Sci 2005 1057 296 318 10.1196/annals.1356.023 16399902 (Pubitemid 43211642)
5. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinon's disease. McNaught KSP, Olanow CW, Ann Neurol 2003 53 (3):S73 S86
6. Biomedicine. Parkinson's divergent causes, convergent mechanisms. Greenamyre JT, Hastings TG, Science 2004 304 (5674):1120 2 15155938
7. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Hald A, Lotharaius J, Exp Neurol 2005 193 279 290 10.1016/j.expneurol.2005.01.013 15869932 (Pubitemid 40616179)
8. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Abou-Sleiman PM, Muqit MM, Wood NW, Nat Rev Neurosci 2006 7 207 219 10.1038/nrn1868 16495942 (Pubitemid 43292466)
9. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Hirsch EC, Hunot S, Lancet Neurol 2009 8 382 397 10.1016/S1474-4422(09)70062-6 19296921
10. Glia as a turning point in the therapeutic strategy of Parkinson's disease. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B, CNS & Neurological Disorders 2010 9 349 372 21761576
11. Glia-Neuron Crosstalk in Neuroinflammation, Neurodegeneration and Neuroprotection. Marchetti B, Kettenmann H, Streit WJ, Brain Res Review S Issue 2005 482 2 129 32
12. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Gao HM, Hong JS, Trends Immunol 2008 29 8 357 65 10.1016/j.it.2008.05.002 18599350
13. To be or not to be (inflammed) is that the question in anti-inflammatory drug therapy of neurodegenerative diseases? Marchetti B, Abbracchio MP, Trends in Pharmacological Sci 2005 26 517 525 10.1016/j.tips.2005.08.007 (Pubitemid 41338562)
14. Glial reactions in Parkinson's disease. McGeer PL, McGeer EG, Mov Disord 2008 23 474 483 10.1002/mds.21751 18044695
15. Pro-regenerative properties of cytokine-activated astrocytes. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW, J Neurochem 2004 89 1092 100 10.1111/j.1471-4159.2004.02420.x 15147501 (Pubitemid 38715826)
16. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA, PNAS 2009 106 8 2933 2938 10.1073/pnas.0813361106 19196989
17. Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M, Tremblay R, Kiuchi K, Sikorska M, Neurobiol of Disease 2009 33 405 414 10.1016/j.nbd.2008.11.016
18. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Blum D, Torch S, Lambeng N, Nissou MF, Benabid AL, Sadoul R, Verna JM, Prog in Neurobiol 2001 65 135 172 10.1016/S0301-0082(01)00003-X (Pubitemid 32524182)
19. Protocol for the MPTP model of Parkinson's disease. Jackson-Lewis V, Przedborski S, Nature Protocols 2007 2 1 141 151 10.1038/nprot.2006.342 17401348 (Pubitemid 47044700)
20. Roles of Wnt proteins in neural development and maintenance. Patapoutian A, Reichardt LF, Curr Opin Neurobiol 2000 10 3 392 399 10.1016/S0959-4388(00) 00100-8 10851180 (Pubitemid 30389308)
21. WNTs in the vertebrate nervous system: From patterning to neuronal connectivity. Ciani L, Salinas PC, Nat Rev Neurosci 2005 6 351 362 15832199 (Pubitemid 40593481)
22. Wnt signaling regulates adult hippocampal neurogenesis. Lie DC, Colamarino SA, Song HG, Désiré L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Diarie AR, Gage FH, Nature 2005 473 1370 1375 (Pubitemid 41568684)
23. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. De Ferrari GF, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC, Mol Psychiatr 2003 8 195 208 10.1038/sj.mp.4001208 (Pubitemid 36315228)
24. Wnt signaling in neuroprotection and stem cell differentiation. Toledo EM, Clombres M, Inestrosa NC, Progr Neurobiol 2008 88 281 296
25. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Toledo EM, Inestrosa NC, Mol Psychiatry 2010 15 272 285 10.1038/mp.2009.72 19621015
26. Cellular demise and inflammatory microglial activation during -amyloid toxicity are governed by WNT1 and canonical signaling pathways. Chong ZZ, Li F, Maiese K, Cell Signal 2007 19 6 1150 1162 10.1016/j.cellsig.2006.12.009 17289346 (Pubitemid 46561553)
27. The Wnt signalling pathway: aging gracefully as a protectionist? Maiese K, Faqi L, Chong ZZ, Chen SY, Pharmacol Ther 2008 118 1 58 81 10.1016/j.pharmthera.2008.01.004 18313758
28. The role of Wnt signalling in neuronal dysfunction in Alzheimer's disease. Inestrosa NC, Toledo EM, Mol Neurodegen 2008 3 9 10.1186/1750-1326-3-9
29. Emerging role of Wnts in the adult nervous system. Inestrosa NC, Arenas E, Nat Rev Neurosci 2009 11 2 77 86 20010950
30. Phosphorylation of tau antagonizes apoptosis by stabilizing -catenin, a mechanism involved in Alzheimers's degeneration. Li HL, Wang LL, Liu SJ, Deng YQ, Zhang YJ, Tian YJ, Wang XC, Chen XQ, Yang Y, Zhang JY, Wang Q, Xu H, Liao FF, Wang JZ, Proc Natl Acad Sci USA 2007 104 3591 3596 10.1073/pnas.0609303104 17360687 (Pubitemid 46364203)
31. Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors. Gordon MD, Nusse R, J Biol Chem 2006 281 22429 22433 10.1074/jbc.R600015200 16793760
32. Beta-catenin is a target for the ubiquitin-proteasome pathway. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R, EMBO J 1997 16 13 3797 804 10.1093/emboj/16.13.3797 9233789 (Pubitemid 27280995)
33. Differential regulation of midbrain dopaminergic neuron development by Wnt1, Wnt3a, and Wnt5a. Castelo-Branco G, Wagner J, Rodriguez FJ, Kele J, Sousa K, Rawal N, Pasolli HA, Fuchs E, Kitajewski J, Arenas E, Proc Natl Acad Sci USA 2003 100 12747 12752 10.1073/pnas.1534900100 14557550 (Pubitemid 37339970)
34. GSK-3 inhibition/-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. Castelo-Branco G, Rawal N, Arenas E, J of Cell Sci 2004 117 5731 5737 10.1242/jcs.01505 (Pubitemid 40123940)
35. Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Castelo-Branco G, Sousa KM, Bryja V, Pinto L, Wagner J, Arenas E, Mol Cell Neurosci 2006 31 2 251 262 10.1016/j.mcn.2005.09.014 16243537 (Pubitemid 43214535)
36. Genetic networks controlling the development of midbrain dopaminergic neurons. Prakash N, Wurst W, J Physiol 2006 575 403 410 10.1113/jphysiol.2006. 113464 16825303 (Pubitemid 44270171)
37. Dynamic temporal and cell type-specific expression of Wnt signaling components in the developing midbrain. Rawal N, Castelo-Branco G, Souse KM, Kele J, Kobayashy K, Okano H, Arenas E, Exp Cell Res 2006 312 1626 1636 10.1016/j.yexcr.2006.01.032 16510140
38. Reactive astrocytes and Wnt/-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C, D'Adamo P, Zardini E, Andreoni L, Ihekwaba AE, Serra PA, Franciotta D, Martino G, Pluchino S, Marchetti B, Neurobiol Dis 2011 41 2 508 527 [Epub 2010 Nov 5] 10.1016/j.nbd.2010.10.023 21056667
39. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. Gao HM, Liu B, Zhang W, Hong JS, FASEB J 2003 17 13 1954 1956 12897068
40. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Semnov MV, Tamai K, Brott BK, Kühl M, Sokol S, He X, Curr Biol 2001 11 12 951 961 10.1016/S0960-9822(01)00290-1 11448771 (Pubitemid 32589186)
41. Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ, Nature 2001 412 86 90 10.1038/35083601 11452312 (Pubitemid 32851515)
42. Wnt signalling promotes regeneration in the retina of adult mammals. Osakada F, Ooto S, Akagi T, Mandai M, Akaike A, Takahashi M, J of Neurosci 2007 27 15 4210 4219 10.1523/JNEUROSCI.4193-06.2007 (Pubitemid 46597155)
43. Role of the Wnt receptor Frizzled-I in presynaptic differentiation and function. Varela-Nallar L, Grabowki CP, Alfaro IE, Alvarez AR, Inestrosa NC, Neural Develop 2009 4 41 10.1186/1749-8104-4-41
44. Interaction of Wnt and a inositol signalling. Slusarski DC, Corces VG, Moon RT, Nature 1976 390 410 413
45. Protein kinase Cis differentially stimulated by Wnt and Frizzled homologs in a G-protein -dependent manner. Shedahl LC, Park M, Malbon CC, Moon RT, Curr Biol 1999 9 695 698 10.1016/S0960-9822(99)80310-8 10395542 (Pubitemid 29332351)
46. Basic fibroblast growth factor (bFGF) acts on both neurons and glia to mediate the neurotrophic effects of astrocytes on LHRH neurons in culture. Gallo F, Morale MC, Spina-Purrello V, Tirolo C, Testa N, Farinella Z, Avola R, Beaudet A, Marchetti B, Synapse 2000 36 233 253 10.1002/(SICI)1098- 2396(20000615)36:4<233::AID-SYN1>3.0.CO;2-I 10819902 (Pubitemid 30257309)
47. Basic fibroblast growth factor priming increases the responsiveness of immortalized hypothalamic luteinizing hormone releasing hormone neurones to neurotrophic factors. Gallo F, Morale MC, Tirolo C, Testa N, Farinella Z, Avola R, Beaudet A, Marchetti B, J Neuroendocrinol 2000 12 10 941 59 11012835
48. Bilirubin protects astrocytes from its own toxicity inducing up-regulation and translocation of multigrug resistance-associated protein 1 (Mrp 1). Gennuso F, Fernetti C, Tirolo C, Testa N, L'Episcopo F, Caniglia S, Morale MC, Ostrow JD, Pascolo L, Tiribelli C, Marchetti B, Proc Natl Acad Sci USA 2004 101 2470 2475 10.1073/pnas.0308452100 14983033 (Pubitemid 38269335)
49. Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymer-based transfection reagents. Brazas RM, Hagstrom JE, Methods Enzymol 2005 392 112 124 15644178 (Pubitemid 40092511)
50. Msx2 exerts bone anabolism via canonical Wnt signaling. Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA, J Biol Chem 2008 283 29 20505 22 10.1074/jbc.M800851200 18487199
51. Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Abeta oligomers. Chacán MA, Varela-Nallar L, Inestrosa NC, J Cell Physiol 2008 217 1 215 27 10.1002/jcp.21497 18521822
52. Interruption of -catenin signaling reduces neurogenesis in Alzheimer's disease. He P, Shen Y, J Neurosci 2009 29 6545 6557 10.1523/JNEUROSCI.0421-09. 2009 19458225
53. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. Morale MC, Serra PA, Delogu MR, Migheli R, Rocchitta G, Tirolo C, Caniglia S, Testa N, L'Episcopo F, Gennuso F, Scoto GM, Barden N, Miele E, Desole MS, Marchetti B, FASEB J 2004 18 1 164 6 14630699
54. The mouse brain in stereotaxic coordinates. Franklin KBJ, Paxinos G, Academic Press Inc 1997
55. Inhibition of glycogen synthase kinase-3 protects dopaminergic neurons from MPTP toxicity. Wang W, Yang Y, Ying C, Li W, Ruan H, Zhu X, You Y, Han Y, Chen R, Wang Y, Li M, Neuropharmacology 2007 52 1678 1684 10.1016/j.neuropharm. 2007.03.017 17517424 (Pubitemid 46843143)
56. Fluoro-Jade: a novel fluorochrome for the sensitive and relialable histochemical localization of neuronal degeneration. Schmued LC, Albertston C, Slikker W Jr, Brain Res 1997 751 37 46 10.1016/S0006-8993(96)01387-X 9098566 (Pubitemid 27122134)
57. Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation. Takeshima T, Johnston JM, Commissiong JW, J Neurosci 1994 14 4769 4779 7913955 (Pubitemid 24237899)
58. Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells. Bournat JC, Brown AM, Soler AP, J Neurosci Res 2000 61 1 21 32 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7 10861796 (Pubitemid 30436471)
59. Wnt signalling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald OA, J of Biol Chem 2002 277 38239 38244 10.1074/jbc.M206402200 (Pubitemid 35154678)
60. The role of Wnt signaling in neuroprotection. Cerpa W, Toledo EM, Varela-Nallar L, Inestrosa NC, Drugs News Perspect 2009 22 579 91 10.1358/dnp.2009.22.10.1443391
61. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3 and attenuated by lithium. King TD, Bijur GN, Jope RS, Brain Res 2001 919 106 114 10.1016/S0006-8993(01)03005-0 11689167 (Pubitemid 33016593)
62. 216 phosphorylation of glycogen synthase kinase-3 in cellular and animal models of neuronal degeneration. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, Lee CM, Proc Natl Acad Sci USA 2000 97 11074 11079 10995469
63. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxy dopamine-induced neuronal death. Chen G, Bower KA, Ma C, Ma C, Fang S, Thiele CJ, Luo J, Faseb J 2004 18 1162 1164 15132987 (Pubitemid 39561557)
64. Differential modulation of Akt/Glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signalling responses. Nair VD, Olanow CW, J Biol Chem 2008 283 22 15469 15478 10.1074/jbc.M707238200 18387957
65. +- treated neurons. Petit-Paitel A, Brau F, Cazareth J. Chabry J, Plos One 2009 4 5 5491 10.1371/journal.pone.0005491 19430525
66. -Synuclein contributes to GSK-3- catalyzed Tau phosphorylation in Parkinson's disease models. Duka T, Duka V, Joyce JN, Sidhu A, Faseb J 2009 23 9 2820 2830 10.1096/fj.08-120410 19369384
67. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Grimes CA, Jope RS, Prog Neurobiol 2001 65 4 391 426 10.1016/S0301-0082(01)00011-9 11527574 (Pubitemid 32781670)
68. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia. Engele J, Bohn MC, J Neurosci 1991 11 10 3070 3078 1941074
69. Cross-talk signals in the CNS: Role of neurotrophic and hormonal factors, adhesion molecules and intercellular signaling agents in luteinizing hormone-releasing hormone (LHRH) neuron-astroglia interactive network. Marchetti B, Trends in Biosci 1997 2 1 32
70. Glutathione metabolism in brain. Metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Dringen J, Gutterer M, Hirrlinger J, Eur J of Biochem 2000 267 4912 4916 (Pubitemid 30641287)
71. Astrocytes: biology and pathology. Sofroniew M, Vinters HB, Act Neuropatology 2010 119 7 35 10.1007/s00401-009-0619-8
72. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. McNaught KSP, Jenner P, J of Neurochem 1999 73 2469
73. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. Mikels AJ, Nusse R, PLoS Biol 2006 4 115 10.1371/journal.pbio.0040115 16602827
74. Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. Cerpa W, Godoy JA, Alfaro I, Farias GG, Metcalfe MJ, Fuentealba R, Bonansco C, Inestrosa NC, J Biol Chem 2008 283 5918 5927 18096705
75. The ups and downs of Wnt signalling in prevalent neurological disorders. De Ferrari GV, Moon RT, Oncogene 2006 25 57 7545 7553 10.1038/sj.onc.1210064 17143299 (Pubitemid 44885754)
76. Members of the Wnt, Fz, and Frp gene families expressed in postnatal mouse cerebral cortex. Shimogori T, VanSant J, Paik E, Grove EA, J Comp Neurol 2004 473 4 496 510 10.1002/cne.20135 15116386 (Pubitemid 38580446)
77. Genome wide atlas of gene expression in the adult mouse brain. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, et al. Nature 2007 445 168 176 10.1038/nature05453 17151600 (Pubitemid 46095716)
78. Downregulation of Wnt/-catenin signalling causes degeneration of hippocampal neurons in vivo. Kim H, Won S, Hwang DY, Lee JS, Kim M, Kim R, Kim W, Cha B, Kim T, Kim D, Costantini F, Jho EH, Neurobiol Aging 2010
79. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Hrupenko SA, Thompson WJ, Barres BA, J Neurosci 2008 28 1 264 78 10.1523/JNEUROSCI.4178-07.2008 18171944
80. Wnt and beyond Wnt: Multiple mechanisms control the transcriptional property of -catenin. Jin T, Fantus IG, Sun J, Cellular Signalling 2008 20 1697 1704 10.1016/j.cellsig.2008.04.014 18555664
81. Wnt/beta-catenin and estrogen signaling converge in vivo. Kouzmenko APK, Takeyama S, Ito T, Furutani S, Sawatsubashi A, Maki E, Suzuki Y, Kawasaki T, Akiyama T, Tabata and Kato S, J Biol Chem 2004 279 40255 40258 10.1074/jbc.C400331200 15304487 (Pubitemid 39287607)
82. A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signalling. Kitagua H, Ray WJ, Glantsching H, Nantermet PV, Yu Y, Leu CT, Harada S, Kato S, Freedman LP, Mol Cell Biol 2007 27 7486 7496 10.1128/MCB.00409-07 17709391 (Pubitemid 350033655)
83. Expression of Wnt receptors in adult spiral ganglion neurons: frizzled 9 localization at growth cones of regenerating neurites. Shah SM, Kang JY, Christensen BL, Feng AS, Kollmar R, Neuroscience 2009 164 478 487 10.1016/j.neuroscience.2009.08.049 19716861
84. Effects of gender on nigral gene expression and parkinson's disease. Cantuti-Castelvetri I, Keller-Mccgandy C, Bouziou B, Asteris G, Clark TW, Frosh MP, Standaert DG, Neurobiol Dis 2007 26 606 614 10.1016/j.nbd.2007.02.009 17412603 (Pubitemid 46756328)
85. GSK3B polymorphism alter transcription and splicing in Parkinson's disease. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, Buchanan DD, Silburn PA, Halliday GM, Schofield PR, Ann Neurol 2005 58 829 839 10.1002/ana.20691 16315267 (Pubitemid 41746872)
86. Characterization of a novel NR4A2 mutation in Parkinson's disease. Sleiman PM, Healy DG, Mugit MM, Yang YX, Van Der Brug M, Holton JL, Revesz T, Quinn NP, Bhatia K, Diss JK, Less Aj, Cookson MR, Latchman DS, Wood NW, Neurosci Lett 2009 457 75 79 10.1016/j.neulet.2009.03.021 19429166
87. Gene expression profiling reveals molecular pathways associated with sporadic Parkinson's disease. Ohnuki T, Nakamura A, Okuyama S, Nakamura S, Brain Research 2010 1346 26 42 20513370
88. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Habig K, Walter M, Poths S, Riess O, Bonin M, Neurogenetics 2008 9 83 94 10.1007/s10048-007-0114-0 18097693
89. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathway. Sancho RM, Law BM, Harvey K, Hum Mol Genet 2009 18 3955 3968 10.1093/hmg/ddp337 19625296
90. Dishevelled:The hub of Wnt signalling. Gao C, Cheng YG, Cell Signal 2010 22 717 727 10.1016/j.cellsig.2009.11.021 20006983
91. Parkin protects dopaminergic neurons from excessive Wnt/-catenin signalling. Rawal N, Corti O, Sacchetti P, Ardilla-Osorio H, Sehat B, Brice A, Arenas E, Biochem Biophys Rws Commun 2009 388 473 478 10.1016/j.bbrc.2009.07.014
92. -catenin siRNA inhibits ischemia-induced striatal neurogenesis in adult rat brain following a transient middle cerebral artery occlusion. Lei Z-NL, Zhang Lin-Mei, Sun F-Y, Neurosci Lett 2008 435 108 112 10.1016/j.neulet.2008.02. 031 18343578
93. Role of Dikkopf-1 (Dkk1), an antagonist of the Wnt - catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of Tau phophorylation. Zhang QG, Wang R, Khan M, Maesh V, Brann DW, J Neurosci 2009 28 8430 8441